The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings indicate that, overall, transgender women exhibited a 2.56-fold lower risk of prostate cancer compared to cisgender men. Specifically, among TW on hormone therapy between ages 50–64, we observed a 2.06-fold decrease in risk. Contrary to the previous perception of prostate cancer being rare in transgender women, our study suggests that it may not be as uncommon as previously believed.

接受医学和手术性别确认干预措施的跨性别女性患前列腺癌的风险仍不清楚，但据报道，与顺性别男性相比，风险降低了五倍。在这项研究中，我们使用大型数据库 TriNetX 和 SEER 的数据对变性女性 (TW) 患前列腺癌的风险进行了比较分析。我们的研究结果表明，总体而言，跨性别女性患前列腺癌的风险比顺性别男性低 2.56 倍。具体而言，在 50-64 岁之间接受激素治疗的 TW 中，我们观察到风险降低了 2.06 倍。与之前认为跨性别女性中前列腺癌罕见的看法相反，我们的研究表明前列腺癌可能并不像之前认为的那么罕见。